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ABSTRACT
The brain is one of the most important organs in the body. It functions as a
control center by regulating and coordinating actions and reactions, which is
facilitated via signal transduction pathways. Its function is primarily dependent
upon sufficient supply of glucose for energy metabolism. The dysfunction of the
brain resulting from an external force is known as traumatic brain injury (TBI).
Symptoms range from physical to psychological and effects can be mild,
moderate, or severe depending on the extent of injury. TBI is associated with
oxidative damage the overproduction of reactive oxygen/nitrogen species.
Reduced energy metabolism is a consequence of traumatic brain injury, while
reduced purine salvage is associated with deficient cell signaling. Previous
studies have demonstrated that the administration of gamma-glutamylcysteine
ethyl ester (GCEE) following TBI has protective effects against protein nitration.
This study investigates the enzymatic activity of energy related and salvage
related enzymes, glyceraldehyde-3-phosphate dehydrogenase, pyruvate kinase,
lactate dehydrogenase, aspartate aminotransferase, malate dehydrogenase,
cytochrome C oxidase, ATP synthase, and hypoxanthine-guanine
phosphoribosyltransferase, that have been identified as excessively nitrated
following the administration of GCEE post-TBI. Adult male Wistar rats were
divided equally into three groups: sham, saline, and GCEE. Rats in all groups
(except sham) were subjected to a craniotomy and a moderate TBI via cortical
contusion. Post-TBI rats in the saline group received an administration of saline
vi

(150mg/kg), and rats in the GCEE treatment group received an administration of
GCEE (same dosage). Upon sacrifice, brains were harvested and enzymatic
activity was indirectly measured spectrophotometrically. Data demonstrates that
the administration of GCEE following brain trauma increases enzymatic activity.
Our results are promising and indicate potential therapeutic strategies to restore
energy and salvage related enzymatic activity in the brain post-TBI.
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CHAPTER 1
INTRODUCTION
Traumatic brain injury (TBI) is a sudden event that results in the disruption
of proper brain functionality and is caused by an external force, such as a blow to
the head. Symptoms range from physical to psychological while effects can be
mild, moderate, or severe depending on the extent of the injury experienced.
Many people who experience TBI face progressive, lifelong physical disabilities
and cognitive impairments. In the past, injury from head trauma was considered
instantaneous and irreversible. Now it is clear that there are two phases of injury:
primary and secondary. Upon insult of injury, the primary physical damage
sustained by the brain alters biochemical and cellular pathways. Secondary
injury then begins as a byproduct of the biochemical and cellular disruptions of
primary injury, and is a progressive cytotoxic cascade causing damage
accumulation, TBI progression, and neurodegeneration, over an extended period
of time.
Membrane depolarization, a direct consequence of primary injury, initiates
the progressive cytotoxic cascade of damage-accumulating events by causing
the uncontrolled release of glutamate in the synaptic gap. The excessive
amounts of glutamate cause the hyper-activation of glutamate receptors, which
consequently cause a mass influx of calcium into the neuronal cells. As a result
of this glutamate-induced excitotoxicity and calcium overload, reactive oxygen
1

(ROS) and reactive nitrogen species (RNS) are overproduced. Typically, the
production of ROS is an aftereffect of oxygen metabolism; however, a host of
studies investigating the molecular and cellular pathophysiological consequences
of traumatic brain injury have found correlated associations with oxidative
damage and protein nitration. Oxidative stress is characterized as an imbalance
between free radicals and antioxidants that result from the body’s inability to
counteract the enhanced formation of ROS/RNS. The suppression of enhanced
reactive oxygen species formation, in part, decreases the production of reactive
nitrogen species, as RNS are derived from ROS interactions with nitric oxide,
peroxynitrite, and peroxynitrite derivatives. Some proteins have an increased
susceptibility to oxidative damage and undergo nitration, which results in
structural and function loss. The culmination of effects from oxidative damage
and protein nitration seen in persons with TBI leads to diminished antioxidant
capacities and increased tissue loss (Shao et al. 2006).
Despite the various elucidations of TBI pathological consequences, no
known federally approved therapeutic agent is available to disrupt its secondary
injury processes. However, several studies demonstrate that therapeutic
approaches utilizing antioxidants effectively prevent neurodegeneration by
protecting neurons against oxidative stress. Innately, cells utilize a host of
mechanisms for protection from ROS. These mechanisms include the
implementations of superoxide dismutase, catalase, and antioxidants. Most
notably, antioxidants, such as glutathione, inhibit oxidation by scavenging
ROS/RNS. In circumstances of ROS/RNS overproduction, these neuroprotective
2

mechanisms are exhausted due to limited availability of substrates. Recent
studies have investigated the administration of chemical substances that boost
intracellular glutathione, as the administration of glutathione itself is ineffective.
Gamma-glutamylcysteine ethyl ester (GCEE) is an ethyl ester moiety of gammaglutamylcysteine, which is a glutathione precursor compound that exhibits
antioxidant activity by increasing glutathione production (Reed et al. 2009).
Previous studies demonstrated that the administration of GCEE following TBI has
protective effects against protein nitration (Reed et al. 2009, Lok et al. 2011).
Mass spectral analysis previously performed by our collaborator, Dr.
Sowell, indicates that energy-related and purine salvage enzymes are nitrated,
thereby resulting in reduced energy metabolism and nucleotide salvage. Thus,
the purpose of this study was to conduct a series of investigations that assessed
the efficacy of GCEE as a neuroprotective therapeutic strategy for TBI by
determining the optimum time point for treatment. The first study (Chapter 4) was
conducted to assess the activity of energy related proteins post-TBI and
determine if the administration of GCEE post-injury normalized enzymatic activity
in experimental TBI brain through its ability to elevate intracellular glutathione
levels and attenuate oxidative stress. The second study (Chapter 5) assessed
and determined the activity of purine salvage enzyme hypoxanthine-guanine
phosphoribosyltransferase with respect to GCEE administrative effects post-TBI.
.
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CHAPTER 2
BACKGROUND
2.1 Traumatic Brain Injury
2.1.1 Overview
Traumatic brain injury is a serious medical issue and public health concern
of significant proportions, as it is a leading cause of death and long-term disability
in disproportionately affected heterogeneous populations worldwide, with an
increasing burden of indirect and direct expenses associated with a lack of
successful therapeutic strategies (Hyder et al. 2007, Bruns and Hauser 2003,
Kabadi and Faden 2014). Higher incidences of traumatic brain injury are reported
in individuals of minority descent and low socioeconomic status (Bruns and
Hauser 2003). Studies confirm that this incidence and prevalence is increased in
early childhood, late adolescence/early adulthood, and elderly populations (Bruns
and Hauser 2003). The high incidence in these groups may be attributed to a
culmination of factors, such as recreational sports, motor vehicle accidents,
reduced motor skills, and physical abuse, according to the National Center for
Injury Prevention and Control at the Centers for Disease Control (CDC). A
collection of studies demonstrate the association of gender differences and TBI
(Bazarian et al. 2010, Farace and Alves 2000, Ottochian et al. 2009). Females
experience higher mortality and fatality rates from traumatic brain injury (Farace
and Alves 2000, Ottochian et al. 2009). Ultimately, evidence suggests that TBI
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can affect virtually everyone, considering risk factors and increasing incidence
and prevalence rates.
2.1.2 Classification
Traumatic brain injury can be classified in numerous ways. These
classifications are determined by characterizations of severity, type, skull
exposure, damage, and injury. Clinically, the use of the Glasgow Coma Scale
(GCS) is the instrument utilized to assess and classify the severity of TBI.
Severity of brain injury can be categorized as mild, moderate, or severe (Table
1). The GCS is comprised of three parameters which evaluate one’s responses
of eye opening, verbal function, and motor function to various stimuli (Teasdale
and Jennett 1974). Scores range from 3 to 15, where a score of 3 is considered
the most severe (diminished capacity) and a score of 15 is considered least
severe (normal ability). Persons receiving a total score of 13 to 15 is considered
to have experienced a mild injury, scores of 9 to 12 are indicative of a moderate
injury, and scores of 3 to 8 are indicative of severe TBI.
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Table 2.1 Glasgow Coma Scale

Response Mechanism
Eye Opening

Verbal Function

Motor Function

Scale
Spontaneously
To speech
To pain only
No response
Oriented
Confused
Inappropriate words
Incomprehensible sounds
No response
Obeys commands
Localizes to pain
Withdraws from pain
Abnormal flexion

Score
4
3
2
1
5
4
3
2
1
6
5
4
3

Severity classification is contingent upon TBI type. The five types of
traumatic brain injury are concussion, contusion, coup-contrecoup injury, diffuse
axonal injury, and penetration (Chung and Khan 2013). The mildest and most
common type of TBI experienced is a concussion. Although it is possible for
anyone to sustain a concussion, recreational and professional athletes have an
inherent risk, as participation in most sporting events involves high velocity
collisional contact (Covassin, Stearne, and Elbin 2008, McKee 2014). Individuals
with a concussion experience a host of medical manifestations, including
headache, confusion, dizziness, blurred vision, tinnitus, hyposmia, hyperacusis,
fatigue, and brief loss of consciousness. These are collectively referred to as
post-concussive somatic symptoms (McAllister and Arciniegas 2002). These
somatic symptoms along with cognitive and behavioral changes experienced
post-concussion are commonly referred to as post-concussion syndrome (PCS),
6

and typically have a brief duration that resolves within weeks (Daneshvar et al.
2011). However, in persons who experience concussions more “routinely”, such
as athletes, the deficits PCS presents can linger for months or longer. The
persistence of PCS along with frequent and repeated incidences of concussions
increase susceptibility of a person developing a more severe TBI.
Contusions and coup-contrecoup injury are moderate forms of TBI that
exert post-concussive somatic symptoms with increased loss of consciousness.
A contusion is characterized as bleeding on the brain that occurs at the site of
impact, whereas in coup-contrecoup injury bleeding is experienced both at and
away from the site of impact. Severe forms of traumatic brain injury include
diffuse axonal injury and penetration. Tearing of brain structures occurs in diffuse
axonal injury, when an object directly breaches through the skull into the brain in
penetration. Persons who experience these severe types of TBI exhibit postconcussive symptoms with extreme loss of consciousness or coma.
Head trauma is classified by skull exposure, which can be referred to as
an open or closed head trauma. This classification is contingent upon the lancing
of the dura mater, one of the three protective layers of the brain. If a head injury
pierces the dura mater, it is considered open; and if it does not it, is classified as
a closed injury. Concussions, contusions, coup-contrecoup injuries, and diffuse
axonal injuries are considered closed head injuries, whereas penetration is
defined as an open head injury. Closed head trauma has inversely proportional
prevalence, mortality, and fatality rates compared to open head trauma, as open
head injury has a lower prevalence but higher mortality and fatality rates (Kazim
7

et al. 2011). Head injury is further categorized by damage distribution. The
distribution of damage in terms of location is referred to as focal or diffuse. If TBI
is focal, damage occurs at the site of impact, with damage localized to those
areas. Alternatively, if TBI is diffuse, damage occurs over a more widespread
area without solid structure impact. Open head trauma tends to be largely focal,
while persons who experience closed head trauma experience focal and diffuse
damage.
Previously, injury from head trauma was considered to be instantaneous
and irreversible. Recent research shows that there are two phases of injury:
primary and secondary (Werner and Engelhard 2007). Primary injury occurs at
the instant the trauma occurs, and represents the immediate resultant physical
damage. Secondary injury begins as a product of disruption from primary injury
and is a progressive cytotoxic cascade causing damage accumulation, and TBI
progression, over an extended period of time. Given that TBI is known to be an
accumulative process, there is potential for improving therapeutic intervention.
2.1.3 Treatment
Currently, there are no FDA approved pharmaceutical interventions to
interrupt or inhibit damage from secondary TBI, despite the attempts of
preclinical studies to assess the efficacy of drugs for neuroprotection (Xiong,
Mahmood, and Chopp 2009). Similarly, approaches to various treatments tested
in clinical trials have all failed to show efficacy with the exception of induced
hypothermia, as they target single factors (Doppenberg, Choi, and Bullock 2004,
Peterson, Carson, and Carney 2008). Targeted temperature management via
8

induction of hypothermia is an approved non-pharmacological approach to TBI,
as it promotes neuronal integrity by inhibiting ischemia inhibition. However,
hypothermia as a treatment for TBI has been recommended for optional and
cautious use, as its benefits are offset by an increased risk of developing
pneumonia (Xiong, Mahmood, and Chopp 2009, Peterson, Carson, and Carney
2008). Given the complexity of primary and secondary injury mechanisms that
exist in traumatic brain injury, neuroprotective strategies should reflect the
cascade of interactive factors that contribute to damage accumulation. Current
research demonstrates therapeutic promise as potential treatments strategically
and simultaneously address the multiple potential effects of injury factors.
Recent investigations of the pleiotropic properties of statins and
cyclosporin A as neuroprotective agents for TBI have resulted in significant
improvement of outcomes after injury. Statins, a class of drugs that ultimately
inhibit the biosynthesis of cholesterol, are typically prescribed to patients in an
effort to prevent heart disease. However, the use of statins demonstrate
beneficial effects unrelated to cholesterol in brain injury models, such as antiinflammatory, antioxidant, anti-excitotoxic, anti-apoptotic, and neurogenic
properties (Wible and Laskowitz 2010). These effects, respective to the wide
therapeutic window for treatment (24 hours), are influential in targeting the
multiple mechanisms of secondary injury by limiting production and expression of
inflammatory mediators, decreasing lipid peroxidation, increasing neuronal
survival, and improving cognitive function (Loane and Faden 2010). Similarly to
statins, cyclosporin A exhibits neuroprotective effects in TBI models, although it
9

is FDA-approved for other clinical purposes and has a large therapeutic window.
This immunosuppressant drug attenuates oxidative stress, lipid peroxidation, and
mitochondrial failure often experienced in post-traumatic brain injury by
stabilizing the mitochondrial permeability transition pore (Kabadi and Faden
2014, Okonkwo and Povlishock 1999).

2.2 Reactive Oxygen and Nitrogen Species
2.2.1 Overview
Reactive oxygen and nitrogen species (ROS/RNS), classified as either
free radicals or as non-radicals, are generated in small amounts by cellular redox
processes, such as the reduction of oxygen in the mitochondria to produce
adenosine triphosphate (ATP) (Trachootham et al. 2008). When produced in
excess ROS/RNS impair cellular homeostasis. Exogenous and endogenous
defense mechanisms exist to combat, decrease, and eliminate excess
ROS/RNS. Examples of these defense mechanisms that restore redox balance
include the cellular antioxidant glutathione as well as a number of enzymes, such
as superoxide dismutase (SOD), catalase, and glutathione peroxidase (GPx)
(Apostolova and Victor 2015).
2.2.2 Free Radicals
Free radicals are species that possess at least one unpaired electron,
whereas non-radicals, such as hydrogen peroxide and peroxynitrite, lack
unpaired electron(s) (Vladimirov 1998). Aside from electron possession, radicals
are characterized by their stability, in terms of reactivity and persistence
10

(Karogodina, Sergeeva, and Stass 2011). Radical stability and reactivity refers to
internal energy level. The higher the energy level, the more unstable the radical
is. Unstable radicals are considered highly reactive because they will attempt to
reach a lower energy level. Hence, free radicals are considered extremely
reactive as they have a great propensity to achieve stability via electron(s)
donation and extraction, while non-radicals are not as reactive as they are more
stable (Halliwell 2006). Persistence of a radical refers to their length of life. Nonradicals are said to have a longer life or persistence than that of a free radical,
because of its stability and low reactivity. Despite differences in persistence,
radicals are generally and collectively short lived.
2.2.3 Oxygen
In terms of ROS, oxygen (O2) is increasingly susceptible to radical
formation, as its lacks paired electrons. The consecutive reduction of oxygen via
electron donation generates a number of ROS, which include, superoxide (•O 2),
hydrogen peroxide (H2O2), and hydroxyl radical (•OH). Diatomic oxygen is also
responsible for the formation of RNS, as peroxynitrite (PN: ONOO-) is produced
by the reaction of nitric oxide (•ON), a reactive nitrogen species (RNS), and •O2.
Thus, it can be said that O2 is important in the derivation of ROS/RNS.

e-

O2 →

+
- e + 2H
O2 →

e- + H+

H2 O2 →

OH•

Fig. 2.1 Formation of hydroxyl radical through electron transfer
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2.2.4 Superoxide, Hydrogen Peroxide, and Hydroxyl Radical
As illustrated in Figure 2.1, superoxide is produced by the reduction of one
molecule of oxygen with an electron. This transfer of an electron to O2 is
conducted by cytochromes within the mitochondria. Given the high reactivity of
•O2, the enzyme superoxide dismutase (SOD) acts as a catalyst to rapidly
facilitate the neutralization of •O2. This neutralization of reactivity involves the
reduction of •O2 to H2O2. Superoxide dismutase is a protein that is commonly
oxidatively modified in neurodegenerative disorders such as Alzheimer’s disease
and Parkinson’s disease (Choi et al. 2005).
In excess accumulation, superoxide and hydrogen peroxide have the
capacity to induce profound effects on mitochondrial function via production of
other ROS (Hall, Vaishnav, and Mustafa 2010). Thus the elimination of H2O2 by
catalase and glutathione proves pivotal in reducing the damaging effects of ROS
(Baud et al. 2004). Catalase and glutathione peroxidase are responsible for the
decomposition of H2O2 into water (H2O) and O2. Hydroxyl radicals are considered
the most toxic ROS, because their ability to react with any molecule to balance
their unpaired electrons is limitless. Secondly, their inability to be eliminated
through enzymatic means, unlike •O2 and H2O2, contribute to their increased
toxicity. Hydroxyl radicals are generated from H2O2 in the presence of high
“catalytic acting” metals. Reactions such as the Fenton reaction demonstrate the
cyclic production of •OH from H2O2 with the aid of metals.
In the Fenton reaction (Fig.2.2), ferrous iron (Fe2+) is oxidized into ferric
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iron (Fe3+), and then reduced by superoxide (Haber and Weiss 1934). The
reduction results in the production of ferrous iron, which can be cycled into
another Fenton reaction (Haber and Weiss 1934). High concentrations of iron
result in an acceleration of radical reactions. Iron-containing proteins, such as
transferrin and hemoglobin, have an overwhelming presence and high affinity for
iron at physiological pH (Halliwell and Gutteridge 1988). Hence, free ionic iron is
almost nonexistent. At conditions in which pH is lowered, the affinity for iron is
reduced within iron storing proteins (Halliwell and Gutteridge 1986). Therefore
this reduction results in the mobilization of iron, which in turn increases the
production of •OH (Halliwell and Gutteridge 1986).

-

H2 O2 + Fe2+ → •OH + OH + Fe3+
Fig.2.2 Fenton Reaction

2.2.5 Nitric Oxide and Peroxynitrite
Though moderately toxic, nitric oxide is involved in many cellular
activities within the body. Uniquely, high concentrations of •ON allow it to
surpass superoxide dismutase in competition for •O2 (Beckman and Koppenol
1996). The coupling of •ON and •O2 produce peroxynititrite. Peroxynitrite is
considered a selective oxidant as its reactivity with biological molecules is
gradual, because it lacks an unpaired electron (Beckman and Koppenol 1996).
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Despite the limited reactivity of PN, its derivatives, such as nitrite radical (•NO2)
and carbonate radical (•CO3), are extremely reactive and very toxic.

2.3 Molecular and Cellular Consequences of Traumatic Brain Injury
2.3.1 Overview
Aside from primary (mechanical) damage, TBI induces a host of
secondary insults that collectively contribute to oxidative damage. Excitotoxicity,
calcium (Ca2+) overload, and reactive oxygen species are the primary
participants in mitochondria-centered cell damage. The culmination of these
sequential contributors ultimately result in lipid peroxidation and protein nitration,
both oxidative protein modifications. Oxidative damage experienced posttraumatic brain injury is irreversible and influential in neurodegeneration.
2.3.2 Glutamate-induced Excitotoxicity
A neurotransmitter is defined as a chemical messenger that facilitates
the transmission of signals between neurons, and can be classified as excitatory
or inhibitory. Excitatory neurotransmitters “excite” or stimulate other neurons
resulting in firing of action potentials, while inhibitory neurotransmitters prevent
the generation of action potentials. Among the host of excitatory
neurotransmitters found in the brain, glutamate is the most abundant. Typically
low concentrations of glutamate are found in the extracellular space. However,
membrane depolarization, a consequence of primary traumatic brain injury,
increases the concentration of glutamate post-TBI due to the lack of inhibition
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regarding glutamate release (Yi and Hazell 2006, Choi 1994, Hartings et al.
2009).
Glutamate excitotoxicity refers to the excessive activation of glutamate
receptors, N-methyl-D-aspartate (NMDA), a-amino-3-hydroxyl-5-methyl-4isoxazolepropionate (AMPA) and kainite (Mark et al. 2001). These receptors are
collectively responsible for the activation of ion channels that promote the influx
of Ca2+ (Mark et al. 2001). The binding of extreme levels of glutamate to these
receptors result in an enormous influx of Ca2+ into neurons, which
consequentially leads to the overproduction of ROS/RNS, excitotoxicity, and
possibly death (Weber 2012).
2.3.3 Overproduction of Reactive Oxygen Species
Mitochondrial uptake of Ca2+ results in the stimulation of ROS
overproduction via mitochondrial permeability transition pore (MPT) activation
(Cheng 2012, Starkov, Cinopoulous, and Fiskum 2004). This activation results in
the release of cytochrome c and loss of intra-mitochondrial glutathione (Starkov,
Cinopoulous, and Fiskum 2004). The release of cytochrome C results in
stimulated •O2 production (Cai, Yang, and Jones 1998). The consequential loss
of intra-mitochondrial glutathione upon MPT activation results in the inability to
detoxify H2O2 and stop the ongoing cascade of ROS production. Although there
are numerous mitochondrial sources that contribute to the overproduction of
ROS, it is important to consider aftereffects of MPT activation, as the electron
transport chain is the primary location of hydroxyl radical production post-TBI.
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2.3.4 Lipid Peroxidation
The brain, being largely composed of polyunsaturated fatty acids, is
extremely susceptible to lipid peroxidation (LP), as the overproduction of ROS
occurs post-TBI (Lok et al. 2011). Lipid peroxidation is defined as the oxidation of
lipids via ROS, and can be divided into three stages: initiation, propagation, and
termination (Fig.2.3). The chain reaction of LP is initiated by the formation of a
lipid radical (•L) via •OH extraction of a hydrogen atom. During lipid peroxidation
propagation, •L readily reacts with •O2 to form a lipid peroxyl radical (•LOO). The
instability and high reactivity of •LOO with lipid hydroperoxide formation
perpetuates the production of other lipid peroxyl radical, until termination.
Termination occurs once lipid availability depletes or stability is achieved via nonradical species production and/or antioxidant detoxification.

Fig.2.3 Illustration of lipid peroxidation
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2.3.5 Protein Nitration
The nitration of proteins leads to a wide variety of structural and functional
consequences, and is induced by the introduction of oxygen and nitrogen
compounds, such as the LP derivatives •CO3 and •NO2. ROS/RNS specifically
target amino acids that contain hydroxyl or amine groups, such as tyrosine and
proline (Corpas et al. 2009). Thus it can be said the level of protein susceptibility
to oxidative and nitrosative damage is contingent upon functional group
possession. In all common forms of TBI, protein dysfunction has been
demonstrated as a consequence of protein nitration (Deng et al. 2007, Orihara et
al. 2001).

2.4 Glutathione
2.4.1 Overview
The ubiquitous tripeptide glutathione, composed of glutamate (Glu),
cysteine (Cys), and glycine (Gly), is an important component of antioxidant
defense, as it behaves as both a substrate for glutathione peroxidase in the
removal of H2O2, and as a free radical scavenger (Winterbourn and Metodiewa
1994). The ability of glutathione to act as an antioxidant is primarily governed by
its active thiol group, which is in the form of a cysteine residue. The antioxidant
stability of glutathione is enhanced by the atypical γ-peptide linkage between Glu
and Cys, which protects glutathione from hydrolysis (Wu et al. 2004). Glutathione
exists in reduced and oxidized forms, GSH and GSSG, respectively. The
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recycling of glutathione, interconversion of GSH to GSSG, is critical for
maintaining redox balance.
2.4.2 Biosynthesis
Glutathione biosynthesis consists of two sequential ATP-dependent
reactions catalyzed by gamma-glutamylcysteine synthetase (GCS) and
glutathione synthetase (GS), and is tightly regulated by GCS, cysteine
availability, and GSH feedback inhibition (Noctor et al. 1997). The initial reaction
consists of the formation of gamma-glutamylcysteine (γ-GluCys) via γ-peptide
linkage between Glu and Cys. Glutathione is then produced via catalysis of γGluCys coupling to Gly.
2.4.3 Metabolism
Glutathione is critical in terms of cellular defense against ROS, as it
functions as an antioxidant. Glutathione effectively participates as a ROS/RNS
scavenger directly by detoxification and indirectly through enzymatic reactions. In
such reactions, •OH, •ON, and ONOO- are removed directly via reduction with
GSH, while enzymatic catalysis by glutathione peroxidase removes H2O2. Both
reactions lead to the generation of oxidized glutathione, which is recycled via
reduction to form GSH using NADPH and glutathione reductase (Dringen 2000)
(Fig.2.4).
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Fig.2.4 Illustration of glutathione recycling

2.4.4 Upregulation of Glutathione
The role of glutathione in maintaining redox equilibrium is immense, as the
loss and eventual depletion of glutathione decreases the reducing capacity of the
cell and increases the levels of ROS/RNS (Martin and Teismann 2009). The high
levels of ROS/RNS associated with glutathione depletion causes oxidative
stress-mediated neuronal dysfunction and death. To ameliorate the deleterious
effects of glutathione depletion and oxidative stress, glutathione levels must be
elevated.
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Strategies to increase glutathione levels have been investigated, as the
administration of crude glutathione has been deemed ineffective (Lash and
Jones 1985, Ammon, Melien, and Verspohl 1986, Wendel and Jaeschke 1982).
Much of the research investigating the upregulation of glutathione biosynthesis
has been aimed at providing cysteine to the cell, as this is the limiting amino acid
in glutathione biosynthesis and exists in the brain at lower concentrations than
Glu and Gly (Drake et al. 2002). Among the glutathione precursors that have
been demonstrated to increase cellular glutathione levels, gammaglutamylcysteine (GCEE) uniquely circumvents the feedback inhibition (Drake et
al. 2002). GCEE, an analog compound of γ-glutamylcysteine with an ethyl ester
moiety addition, has been demonstrated to have neuroprotective effects against
protein nitration and oxidative stress through glutathione elevation (Reed et al.
2009, Drake et al. 2002, Lok et al. 2011).
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CHAPTER 3
EXPERIMENTAL METHODS
3.1 Controlled Cortical Impact
TBI is a disease of great complexity, as there is no known drug to interrupt
and inhibit its pathological consequences. However, the utilization of animal
models in TBI research aids in the identification and assessment of potential
neuroprotective therapeutics. Given the varying heterogeneities of TBI, such as
physical, behavioral, and histopathological changes, the use of animal models
are preferred as researchers are able to investigate single factors in the
pathobiology through experimental design. Whereas the constraints of
experimental control in human subjects TBI research is limited as the injury type,
severity, and condition change dynamically.
In lieu of the heterogeneous nature of TBI, experimental designs to induce
TBI vary, and include fluid percussion injury model, controlled cortical impact
(CCI) injury model, penetrating ballistic-like injury model, weight drop model, and
blast model, (Xiong, Mahmood, and Chopp 2013). The selection of an injury
model to implement in experimental design is based upon its varying strengths
and weaknesses in regards to the research question. In this study, CCI was
selected as the injury model of use for a number of reasons. Our primary reason
for this choice was the ease in manipulating mechanical factors, such as time,
velocity, and impact depth, allowing for the selection of injury severity induced.
CCI also can focally localize injury, decreasing the risk of rebound injury.
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Upon approval of animal surgical procedures by the University of Kentucky
Institutional Animal Care and Use Committee, animals were housed in the
Division of Laboratory Animal Resources at the University of Kentucky in a 12
hour light/dark cycle with ad libitum access to feed. Eighteen adult male Wistar
rats (Harlan Laboratories, Indianapolis, IN, USA) were equally divided into three
experimental groups: sham, saline, and GCEE. Animals were shaved to remove
hair on the scalp and anesthetized using isoflurane (3.0%) prior to being placed
in a stereotaxic frame (David Kopf Instruments, Tujunga, CA) for surgery.
Surgery was completed and conducted in the same fashion as previously
described by Sullivan (Sullivan et al. 2002). Upon placement in the frame, rats
underwent a craniotomy, a surgical process that allows access to the brain via
skull cap removal. A metal ball was dropped from the impactor on the cortex of
the exposed brains of the vehicle and treatment groups, saline and GCEE
respectively, at a 1.5 mm depth to simulate a moderate TBI, in the form of
contusion. A 4 mm disk made from dental cement was placed over the site of the
surgery and/or injury and adhered to the skull with cyanoacrylate. The skull cap
was then returned and the skin was sutured. Rats were placed on a heating pad
until consciousness and mobility were regained.
3.2 Spectrophotometric Enzyme Assays
Proteins have a host of functions within cells. Proteins termed enzymes
are biological catalysts that work by lowering activation energy. A large number
of studies indicate that posttranslational modifications of proteins, such as
nitration and oxidation, alter protein function. Reductions in energy metabolism
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and protein catabolism have been reported post-TBI (Weinzierl et al. 2002, Yao,
Liu, and McCabe 2007). In an effort to assess the activity of energy related and
purine salvage enzymes post-TBI, various spectrophotometric enzyme assays
were conducted in this research study.
The use of spectrophotometric assays allowed the detection of changes in
substrate absorbance values. This change was measured by the appearance of
product or the disappearance of substrate. In circumstances in which substrates
or products were incapable of absorbing light at wavelengths detectable by the
spectrophotometer, reactions were coupled. In coupling reactions, the product of
one reaction is used as a substrate for another reaction.
All reagents utilized in the assay reaction mixtures were prepared in
deionized water or buffer specific to the enzyme of interest. Appropriate volumes
of reaction reagents and enzymes were added to each respective microplate to
reach a final volume of 200 µL per well. Microplate wells serving as negative
controls (“blank”) lack test samples and enzyme, and have an increased volume
of buffer in comparison to wells housing enzyme and samples. Wells containing
the enzyme of interest or samples are respectively referred to as positive controls
and analytes. The addition of equivalent volumes of enzyme or samples in wells
respective to their designation initiates the reactions. Upon initiation, the
reactions were incubated and monitored at specific wavelengths and
temperatures for 15 minutes using a plate reader. All reactions in each assay are
performed in triplicate and incubated at room temperature unless noted
otherwise.
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3.2.1 Glyceraldehyde-3-phosphate dehydrogenase
Glyceraldehyde-3-phosphate dehydrogenase (GAPDH) is the
oxidoreductase responsible for many processes in glycolysis, such as producing
ATP through substrate level phosphorylation and reducing NAD+ to NADH. Apart
from its role in glucose metabolism, GAPDH acts as an intracellular sensor of
oxidative stress in the initiation of apoptosis, and is involved in membrane
trafficking and nuclear translocation (Chuang, Hough, and Senatorov 2005,
Ventura et al. 2010, Tristan et al. 2011). Given its wide array of participation in
cellular events, aberrant activity is suggestive of pathological consequences,
such as abnormal cell proliferation and carcinogenesis. Thus the quantitation of
glyceraldehyde-3-phosphate dehydrogenase provides insight into normal cellular
physiology and the detection of disease.
The GAPDH assay is a coupled spectrophotometric assay used in
indirectly measuring the activity of GAPDH via determination of the number of
moles of glycerate-1,3 bisphosphate converted to glyceraldehyde-3-phosphate at
340 nm (Fig.3.1). In this assay, the substrate, glycerate-1,3 bisphosphate is
produced by the ATP-dependent phosphorylation of 3-phosphoglyceric acid (3PGA) catalyzed by 3-phosphoglyceric phosphokinase (3-PGK) (Fig.3.1, step 1).
Then glycerate-1,3 bisphosphate is reduced by β-nicotinamide adenine
dinucleotide (β-NADH) to glyceraldehyde-3-phosphate (G-3-P) and inorganic
phosphate in the presence of glyceraldehyde-3-phosphate dehydrogenase
(Fig.3.1, step 2).
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Fig.3.1 Enzymatic reaction of glyceraldehyde-3-phosphate dehydrogenase assay

All reagents were prepared using deionized water, with the exception of
the GAPDH enzyme solution, which was prepared using 100 mM triethanolamine
buffer (pH 7.6). Reaction reagents, as found in Table 3.1, were added to the
microplate and mixed prior to insertion into the plate reader.

Table 3.1 Glyceraldehyde-3-phosphate dehydrogenase assay reagents
(volume per well)

Reagent

Blank

100 mM Triethanolamine hydrochloride
100 mM D(-) 3-phosphoglyceric acid
200 mM L-cysteine hydrochloride
7 mM β-NADH
100 mM MgSO4
34 mM ATP
200 U/mL 3-phosphoglyceric
phosphokinase
0.6 U/mL GAPDH enzyme solution
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166.8 µL
13.3 µL
3.3 µL
3.3 µL
3.3 µL
6.7 µL
3.3 µL

Positive
Control
160 µL
13.3 µL
3.3 µL
3.3 µL
3.3 µL
6.7 µL
3.3 µL

-

6.8 µL

3.2.2 Pyruvate kinase
Pyruvate kinase (PK) is an essential enzyme in glucose metabolism as it
catalyzes the conversion of phosphoenolpyruvate (PEP) into pyruvate, and
assists in the production of ATP via phosphoryl group transfer from PEP to
adenosine diphosphate (ADP), in the final irreversible step of glycolysis (Fig.3.2).
Pyruvate produced from this reaction serves as an intermediate in connecting
glycolysis and the TCA cycle. Thus the strict regulation of PK activity is of
immense importance in overall cellular metabolism. The pyruvate kinase assay, a
coupled enzyme assay, is often implemented to assess the enzymatic activity of
PK, as defects in activity impede glycolysis, while the absence of PK is causal to
the development of hemolytic anemia. This two-step reaction assay is monitored
at 340 nm upon initiation, and results in the generation of pyruvate and ATP
(Fig.3.2, step 1). Pyruvate produced in the initial reaction is used as a substrate
to produce lactate in the second reaction via coupling with β-NADH in the
presence of lactic dehydrogenase (LDH) (Fig.3.2, step 2).
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Fig.3.2 Enzymatic reaction of pyruvate kinase assay

All reagents found in Table 3.2 were prepared using deionized water, with
the exception of L-lactic dehydrogenase and pyruvate kinase enzyme solutions,
which were prepared using 100 mM KH2PO4 buffer (pH 7.6 at 37°C). The
reaction mixture was mixed and equilibrated to 37°C. Pyruvate kinase enzyme
solution or sample was then added to initiate the reaction.
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Table 3.2 Pyruvate kinase assay reagents (volume per well)

Reagent
dH2O
100 mM KH2PO4
8 mM PEP
3 mM β-NADH
100 mM MgSO4
40 mM ADP
500 U/mL LDH
0.6 U/mL PK

Blank
93.3 µL
53.3 µL
10.7 µL
13.3 µL
13.3 µL
6.7 µL
2.7 µL
-

Positive Control
93.3 µL
60 µL
10.7 µL
13.3 µL
13.3 µL
6.7 µL
2.7 µL
6.7 µL

3.2.3 Lactate dehydrogenase
Lactate dehydrogenase (LDH), an oxidoreductase responsible for the
reduction of pyruvate to lactate (Fig 3.3), is present in a wide variety of tissues
within the body. LDH levels are elevated and released into the bloodstream upon
injury, disease, or exposure to toxic material. Thus, clinical quantification of this
enzyme is used to investigate pathological conditions and assess tissue damage
and toxicity.

Fig 3.3 Enzymatic reaction of lactate dehydrogenase

28

In assaying the activity of LDH post-TBI, all reaction reagents were
prepared using 100 Mm NaH2PO4 (pH 7.5 at 37°C), with the exception of the
enzyme which was prepared in 1.0% (w/v) BSA solution. Upon preparation,
reaction reagents were added to a microplate in specific volumes (Table 3.3),
where they were mixed and incubated at 37°C for 5 minutes prior to being placed
and monitored in a plate reader at 340 nm.

Table 3.3 Lactate dehydrogenase assay reagents (volume per well)

Reagent
0.13 mM β-NADH
34 mM Sodium Pyruvate
1.0 % BSA
0.5 U/mL LDH

Blank
186.6 µL
6.7 µL
6.7 µL
-

Positive Control
186.6 µL
6.7 µL
6.7 µL

3.2.4 Aspartate aminotransferase
Aspartate aminotransferase (AST), also known as serum glutamic
oxaloacetic transaminase, facilitates and accelerates the reversible conversion of
aspartate and α-ketoglutarate to oxaloacetate and glutamate (Figure 3.4). AST is
not organ specific and can primarily be found in significant amounts in the liver
and heart, with minimal amounts in the kidneys and brain. Damage experienced
by these organs result in the elevation of AST levels in serum. Serum levels
typically correlate with the extent of damage experienced. Measurement of AST
activity following brain injury via coupled kinetic photometric analysis offers
insight regarding the role of amino acid metabolism in the TCA cycle.
29

Fig.3.4 Enzymatic reaction of aspartate aminotransferase

To assay the activity of aspartate aminotransferase, the reagent cocktail
was prepared as described in Table 3.4. AST enzyme solution (0.25 U/mL) was
prepared in a 100 Mm KH2PO4 (pH 7.4). The reaction was monitored at 340 nm,
loading the volumes of reagents and enzyme according to Table 3.5.

Table 3.4 Aspartate aminotransferase assay cocktail mixture

Reagent
L-aspartic acid
α-ketoglutaric acid
β-NADH
LDH
malate dehydrogenase
KH2PO4 buffer

30

Concentration
134 mM
6.64 mM
0.24 mM
5 U/mL
1.25 U/mL
50 mM

Table 3.5 Aspartate aminotransferase assay reagents (volume per well)

Reagents

Blank

AST assay cocktail mixture
AST enzyme solution

200 µL
-

Positive
Control
195 µL
5 µL

3.2.5 Malate dehydrogenase
Malate dehydrogenase (MDH) is an oxidoreductase enzyme that
participates in the reversible catalysis of the conversion of L-malate to
oxaloacetate using NAD+ (Fig.3.5). Research indicates increased MDH activity in
Alzheimer’s disease is consequential of oxidative stress (Shi and Gibson 2011).
Thus, quantifying the activity of MDH post-TBI provides insight into the
correlation of oxidative stress and neurodegenerative diseases. Prior to loading
wells (Fig.3.5), assay reagents and enzymes were prepared in 100 mM KH2PO4
buffer (pH 7.4). This assay was monitored at 340 nm in a plate reader.

NAD+

COOHO

C

NADH

H

CH2

COOO

MDH

C
CH2

COO-

COO-

malate

oxaloacetate

Fig.3.5 Enzymatic reaction of malate dehydrogenase
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+

H+

Table 3.6 Malate dehydrogenase assay reagents (volume per well)

Reagents
100 mM KH2PO4
3.75 mM β-NADH
6 mM Oxaloacetate
5 U/mL MDH enzyme
solution

Blank
180 µL
13.3 µL
6.7 µL
-

Positive Control
175 µL
13.3 µL
6.7 µL
5 µL

3.2.6 Cytochrome C oxidase
Cytochrome C oxidase (Cyt-c) is a mitochondrial enzyme that catalyzes
the conversion of molecular oxygen to water (Fig.3.6), in Complex IV of the
respiratory chain, and functions in providing energy to the cell via coupling
electron transport and oxidative phosphorylation. Cyt-c activity is based upon the
photometric assessment of the decrease in absorbance of reduced cytochrome c
at 550 nm, which occurs subsequently after oxidation by Cyt-c (Fig.3.6).

Cytochrome c (reduced) + 2H+ +

Cyt-c
1
O2 →
Cytochrome c (oxidized) + H2 O
2

Fig.3.6 Enzymatic reaction of cytochrome C oxidase

All reagents utilized in this assay were prepared in 100 mM KH2PO4 buffer
(pH 7.4 at 37°C), with the exception of reduced cytochrome c and cytochrome C
oxidase enzyme. Cytochrome c was prepared in 10 mM KH2PO4 buffer and
reduced using 5 mg of ascorbic acid. The cytochrome C and ascorbic acid
solution was then placed in a cellophane membrane, and was dialyzed in 10 mM
KH2PO4 buffer for 24 hours in efforts to remove excess ascorbic acid from the
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dialysate (cytochrome C and ascorbic acid solution). The cytochrome C oxidase
enzyme was prepared in 250 mM sucrose solution with 1% Tween 80 (v/v).
Reagents and enzyme were added to the microplate as described in Table 3.7,
with the addition of test samples, which were added in equivalent volumes to the
enzyme. Reactions in the microplate were equilibrated to 37°C prior to
spectrophotometric analyses.

Table 3.7 Cytochrome C oxidase assay reagents (volume per well)

Reagents
10 mM KH2PO4
1.0 % (w/v) reduced
cytochrome c
100 mM potassium ferricyanide
0.02 mg/mL Cyt-c enzyme
solution

Blank
180 µL
13.3 µL

Positive Control
180 µL
13.3 µL

6.7 µL
-

6.7 µL

3.2.7 ATP synthase
ATP synthase is a membrane protein that plays a pivotal role in energy
metabolism, as it is responsible for catalyzing the phosphorylation of ADP to ATP
(Fig 3.7). A deficiency or decrease in ATP synthase activity results in impaired
ATP production. To determine ATP synthase activity, assay reagents were
prepared in Tris buffer (pH 8.0) and loaded into microplate wells in volumes
described in Table 3.8. This assay was monitored spectrophotometrically at 340
nm via the indirect reactions of LDH and PK.
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Fig.3.7 Enzymatic reaction of ATP synthase assay

Table 3.8 ATP synthase reagents (volume per well)

Reagent
100 mM Tris base
2 mM MgCl2
50 mM KCl
0.2 mM EDTA
0.23 mM β-NADH
1 mM PEP
1.4 U/mL PK/LDH

Blank
6 µL
5 µL
5 µL
5 µL
170 µL
9 µL
-

Positive Control
5 µL
5 µL
5 µL
5 µL
170 µL
9 µL
1 µL
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Test Sample
1 µL
5 µL
5 µL
5 µL
170 µL
9 µL
-

3.2.8 Hypoxanthine-guanine phosphoribosyltransferase
Purines are nitrogenous-based precursors in DNA/RNA synthesis that can
be synthesized de novo or recycled by salvage pathways. Purine salvage is said
to save the energetic cost of de novo synthesis, as it forms purine nucleoside
monophosphates by attaching purine bases derived from the degradation of
nucleic acids and nucleotides to 5-phosphoribosyl-1-pyrophosphate (PRPP).
Hypoxanthine-guanine phosphoribosyltransferase (HGPRT) is a salvage enzyme
responsible for converting hypoxanthine to inosine monophosphate (IMP)
(Fig.3.8 reaction 1) and guanine to guanosine monophosphate (GMP) (Fig.3.8
reaction 2). Deficiency in HGPRT activity clinically manifests as Lesch-Nyhan
syndrome, a severe neurological disorder characterized by uncontrollable selfmutilation and the overproduction of uric acid.
In assaying the activity of HGPRT, reaction reagents were prepared
according to the PRECICE® HPRT Assay Kit protocol obtained from Novocib
(http://www.novocib.com/HPRT_Assay_Kit.html). Briefly, reaction mixture 1x
without PRPP was prepared by dissolving dithiothreitol, nicotinamide adenine
dinucleotide, bacterial inosine-5’-monophosphate dehydrogenase in 1 mL of
reaction buffer 10x containing hypoxanthine. Reaction mixture 1x with PRPP was
prepared similarly, with the addition of 2 mM PRPP. Human recombinant HPRT
enzyme solution (75 mU/mL) was prepared using deionized water. Loaded
volume of assay reagents per well are displayed in Table 3.9. This assay was
monitored at 340 nm.
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Fig.3.8 Enzymatic reactions of hypoxanthine-guanine
phosphoribosyltransferase

Table 3.9 Hypoxanthine-guanine phosphoribosyltransferase reagents
(volume per well)

Reagent
Reaction 1x without PRPP
Reaction 1x with 2 mM PRPP
75 mU/mL HGPRT enzyme

Blank
200 µL
-
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Positive Control
195 µL
5 µL

CHAPTER 4
ENZYME ANALYSIS OF SPECIFIC ENERGY RELATED ENZYMES
NITRATED BY MODERATE TRAUMATIC BRAIN INJURY
4.1 Overview
Proper brain functionality is dependent upon a sufficient supply of
glucose for energy metabolism. Thus, biochemical processes involved in cellular
respiration are important in producing ATP for the brain. Reduced energy
metabolism and mitochondrial dysfunction are associated with traumatic brain
injury, as studies have demonstrated that protein nitration is a consequence of
TBI through the production of ROS/RNS (Deng et al. 2007, Orihara et al. 2001).
Antioxidants, such as glutathione, combat the deleterious effects of oxidation
by scavenging ROS/RNS, inhibiting propagation of lipid peroxyl radicals, and
removing neurotoxic byproducts such as 4-hydroxynonenal, acrolein, and
malondialdehyde. GCEE, an ethyl ester moiety of gamma-glutamylcysteine,
exhibits antioxidant activity by increasing glutathione production. Previous
studies have demonstrated that the administration of GCEE following TBI has
protective effects against protein nitration through the elevation of glutathione
(Reed et al. 2009, Drake et al. 2002, Lok et al. 2011). This study used controlled

cortical impact on Wistar rats to induce TBI. This choice in experimental TBI
model permitted the observation of neurological and pathological changes that
contribute to secondary injury based upon severity of injury induced (Potts et al
2009, Dixon et al 1991) From brain homogenate, enzymatic activity of energy
related proteins that have been identified as nitrated in moderate TBI were
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studied. Results demonstrate an increase in enzymatic activity upon GSH
elevation via GCEE administration in several key enzymes including
glyceraldehyde-3-phosphate dehydrogenase, pyruvate kinase, lactate
dehydrogenase, aspartate aminotransferase, malate dehydrogenase,
cytochrome C oxidase, and ATP synthase, thereby indicating GCEE is a
potential therapeutic strategy to restore energy related proteins in the brain postTBI via GSH elevation.

4.2 Introduction
Traumatic brain injury is a sudden spontaneous event in which brain
dysfunction occurs as a result of an external force. The dysfunction experienced
is a result of the external physical impact occurring at the site of injury, and is
termed primary damage. Primary damage subsequently initiates immediate or
delayed physiological disturbances, known as secondary damage, which
collectively result in mitochondrial dysfunction. After TBI, the mitochondria
experience an affluence of toxic radical species that decrease ATP production.
Mitochondrial ATP production typically occurs through a cascade of
reactions, in which electrons carried by NADH and FADH2 interact with O2 via a
respiratory proton pump (Pieczenik and Neustadt 2007). In the pathological
circumstances of traumatic brain injury, ATP production is often limited due to
nitration of enzymes responsible for facilitating the biochemical reactions of
cellular respiration. The scavenging of ROS/RNS is protective against oxidative
stress; however, the antioxidant glutathione exists in the brain at lower
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concentrations than other organs and is easily depleted post-TBI (Lok et al.
2011, Dringen 2000). Strategies that increase glutathione concentrations post
brain injury, such as GCEE, show therapeutic promise in protecting proteins
against nitration and neurons against oxidative stress.
In this study, we assessed the efficacy of GCEE as a therapeutic
strategy in the overall restoration of brain energy metabolism via glutathione
elevation following the onset of injury. Energy-related enzymes were assayed at
various time points to determine the optimum time point for treatment.

4.3 Materials and Methods
4.3.1 Chemicals and Materials
All chemicals utilized were obtained from Sigma-Aldrich (St Louis, MO,
USA) with the exception of GCEE, purchased from Bachem (Torence, CA, USA),
β-NADH and Tris Base, which was purchased from Thermo Fisher Scientific
(Waltham, MA, USA).
4.3.2 Surgical, Treatment, and Sample Preparation
Please refer to Chapter 3, sections 3.1.1, for information regarding
surgical procedures. Sham animals served as the control, and were not injured or
treated. Saline and GCEE animals received a moderate CCI and an
intraperitoneal injection of saline or GCEE (150 mg/kg) according to their
corresponding experimental groupings, at either 30 or 60 minutes post-injury. All
rats were sacrificed via decapitation 24 hours post-injury. Upon sacrifice, whole
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brain was harvested, suspended, sonicated, and homogenized in 10 mM HEPES
buffer (pH 7.4), containing 137 mM NaCl, 4.6 mM MgSO4, as well as proteinase
inhibitors leupeptin (0.5 mg/mL), pepstatin (0.7 ug/Ml), type II soybean trypsin
inhibitor (0.5 µg/mL), and PMSF (40 µg/mL). Brain homogenates were
centrifuged to remove debris at 14,000 x g for 10 minutes, and supernatant was
collected.
4.3.3 Glyceraldehyde-3-phosphate dehydrogenase assay
The enzymatic activity of glyceraldehyde-3-phosphate dehydrogenase
assay (GAPDH) was determined through the glycerate-1,3 biphosphate coupled
assay at 340 nm. In the assay, the 0.2 mL reaction mixture contained 100 mM
triethanolamine hydrochloride pH 7.6, 100 mM D(-)3-phosphoglyceric acid
(cyclohexylammonium) salt, 200 mM L-cysteine hydrochloride monohydrate, 100
mM MgSO4, 7 mM β-NADH, 34 mM ATP, and 200 units 3-phosphoglyceric
phosophokinase. The addition of 6.8 µL of GAPDH or brain sample initiated the
reaction. Upon initiation, the reaction was monitored at room temperature for 15
minutes in a microplate reader. One unit of GAPDH will reduce one micromole of
3-phosphoglycerate to D-glyceraldehyde-3-phosphate per minute under the
conditions previously mentioned.
4.3.4 Pyruvate kinase assay
The spectrophotometric determination of pyruvate kinase (PK)
enzymatic activity coupled the production of pyruvate to the oxidation of β-NADH
via PK and lactate dehydrogenase (LDH) reactions, which were equilibrated to
37o C and monitored at 340 nm for 15 minutes in a microplate reader. The 0.2
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mL reaction mixture contained 100 mM KH2PO4 (pH 7.6), 8 mM
phosphoenolpyruvate (PEP), 3 mM β-NADH, 100 mM MgSO4, 40 mM ADP, and
500 units LDH. The reaction was initiated by the addition of 6.7 µL of enzyme or
brain sample. One unit of activity is the amount of PK catalyzing the conversion
of PEP to pyruvate and one unit of LDH reducing 1.0 µmole of pyruvate to Llactate per minute.
4.3.5 Lactate dehydrogenase assay
Lactate dehydrogenase (LDH) activity was quantified by the change in
absorption at 340 nm resulting from the oxidation of β-NADH in a microplate
reader. The reaction mixture, containing 0.13 mM β-NADH, 34 mM sodium
pyruvate, and 1.0% (w/v) BSA, was started upon the addition of 6.7 µL of LDH
enzyme or brain sample and equilibrated to 37°C. One unit of LDH activity will
reduce 1.0 µmole of pyruvate to l-lactate per minute at pH 7.5 at 37o C. This
assay was conducted for 15 minutes.
4.3.6 Aspartate aminotransferase assay
The activity of aspartate aminotransferase (AST) was measured
spectrophotometrically at 340 nm for 15 minutes by MDH coupled
spectrophotometric assay. The standard reaction mixture contained 134 mM Laspartic acid (pH 7.4), 6.64 mM of α-ketoglutaric acid, 240 mM β-NADH, 5 units
LDH, 1.25 units MDH, and 50 mM Na3PO4. The addition of five microliters of AST
enzyme or brain sample at room temperature initiated the reaction. This assay
was carried out using a microplate reader. Under the conditions mentioned
above, one unit oxidizes one micromole of β-NADH per minute.
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4.3.7 Malate dehydrogenase assay
MDH activity was determined spectrophotometrically at room
temperature using a microplate reader to quantify the decrease in absorbance at
340 nm for 15 minutes. The reaction mixture contained 100 mM of KH2PO4 pH
7.4, 6 mM oxaloacetic acid, and 3.75 Mm β-NADH. The addition of five microliters
of MDH or brain sample to reaction mixture initiated the assay. One unit of
malate dehydrogenase catalyzes the conversion of one micromole of oxaloacetic
acid and β-NADH to L-malate and β-NAD+ per minute.
4.3.8 Cytochrome c oxidase assay
The enzymatic activity of cytochrome c oxidase was assayed at 550 nm
for 15 minutes using a microplate reader. Prior to performing this assay, a stock
solution containing ten milligrams per milliliter of Cyt-c was reduced with excess
sodium L-ascorbate, and then dialyzed before use. The reaction mixture
contained 2 µg of reduced cytochrome C and 10 mM KH2PO4 (pH 7). A complete
reaction mixture along with the addition of 100 mM K3Fe(CN)6 served as the
blank. The reaction was started by the addition of 6.7 µL of Cyt-c or brain sample
and equilibrated at 37oC. One unit of cytochrome c oxidase oxidizes one
micromole of reduced Cyt-c to oxidized Cyt-c per minute.
4.3.9 ATP Synthase assay
The activity of ATP synthase was determined via PK-LDH coupled
assay. Standard reaction mixture contained 100 mM Tris pH 8, 2 mM MgCl 2, 50
mM KCl, 0.2 mM EDTA, 0.23 β-NADH, 1 mM PEP. The addition of 1.4 units PK
and 1.4 units LDH to the reaction mixture served as the enzyme control. This
42

reaction was initiated upon the addition of 1 microliter of PK/LDH enzyme or
brain sample and was assayed at 30oC using a microplate reader.
4.3.10 Statistical Analysis
All data were analyzed using ANOVA (two-way) and statistical significance was
set at p < 0.05. Tukey’s adjustments were made for ANOVA to determine which
treatments were significant.
4.4 Results
4.4.1 Glyceraldehyde-3-phosphate dehydrogenase activity

Fig.4.1 Activity of glyceraldehyde-3-phosphate dehydrogenase in traumatically
brain injured GCEE treated animals compared to saline treated and sham animals.
Bars are representative of mean ± S.E.M., n = 3 for each group.

The glyceraldehyde-3-phosphate dehydrogenase assay was performed
to assess the enzyme activity of GAPDH upon traumatic brain injury in rats and
the efficacy of GCEE in restoring GAPDH enzyme activity. The administration of
saline and GCEE following TBI shows an increase in the enzyme activity of
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glyceraldehyde-3-phosphate dehydrogenase compared to sham, but was not
statistically significant (p > 0.05). The administration of saline 30 minutes post
injury had a greater effect on the rats in comparison to those treated with saline
60 minutes post-TBI; whereas, the administration of GCEE 60 minutes post-TBI
had a greater effect on the rats in comparison to those treated with GCEE 30
minutes post-injury. However, the differences in treatment time were marginally
statistically significant compared to controls (p = 0.0593).
4.4.2 Pyruvate kinase activity

**
*

Fig.4.2 Activity of pyruvate kinase in traumatically brain injured GCEE treated
animals compared to saline treated and sham animals. Bars are representative of
mean ± S.E.M., n = 3 for each group, *p = 0.0254, **p = 0.0226.

The catalytic activity of PK using the pyruvate kinase assay was
determined. A non-significant reduction in activity was observed following the
administration of saline 30 minutes after injury compared to sham, but increased
within 60 minutes (Fig.4.2). PK activity significantly increased post injury
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following the administration of GCEE 30 and 60 minutes post-TBI compared to
sham and saline treated animals (p = 0.0129), with an elevation in activity at 60
minutes.
4.4.3 Lactate dehydrogenase activity

Fig.4.3 Activity of lactate dehydrogenase in traumatically brain injured GCEE
treated animals compared to saline treated and sham animals. Bars are
representative of mean ± S.E.M., n = 3 for each group.

The utilization of the lactate dehydrogenase assay quantified the activity
of LDH. The administration of saline and GCEE at 30 and 60 minutes post-injury
increased LDH activity compared to the control. However, this was not a
significant increase (p > 0.05). Although the administration of both saline and
GCEE 60 minutes post-injury had a more pronounced effect on rats in
comparison to those treated at 30 minutes post-injury, the elevation in activity
was non-significant (p > 0.05).
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4.4.4 Aspartate aminotransferase activity

*

Fig.4.4 Activity of aspartate aminotransferase in traumatically brain injured GCEE
treated animals compared to saline treated and sham animals. Bars are
representative of mean ± S.E.M., n = 3 for each group, *p = 0.0013.

The activity of aspartate aminotransferase corresponding to the
administrative effect of treatment was quantified using the AST assay.
Measurements of aspartate aminotransferase activity in traumatically brain
injured rats demonstrated a slight reduction following saline administration 30
minutes after injury compared to sham, but significantly increased within 60
minutes compared to saline administered 30 minutes following traumatic brain
injury (p = 0.0013). The administration of GCEE post-TBI increased activity
compared to sham and saline treated animals sans significance (p > 0.05);
however, the administration of GCEE 60 increased activity compared to GCEE
administered 30 minutes post injury was statistically significant (p = 0.0013).
Observations of the effect of time of treatment demonstrated significance, where
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administration of saline and GCEE 60 minutes upon injury increased enzyme
activity compared to administration at 30 minutes (Fig.4.4).
4.4.5 Malate dehydrogenase activity

*
**

***

***

Fig.4.5 Activity of malate dehydrogenase in traumatically brain injured GCEE
treated animals compared to saline treated and sham animals. Bars are
representative of mean ± S.E.M., n = 3 for each group, *p = 0.0024, **p = 0.0200,
***p < 0.001.

Using the MDH assay, enzyme activity of MDH was measured post
incident administration of treatment. Results indicate the administration of vehicle
(saline) and drug significantly increased activity compared to sham (p = 0.0025).
A more robust significant increase in activity was observed following the
administration of saline and GCEE 60 minutes post-TBI, in comparison to
administration at 30 minutes (p < 0.001). Statistical analyses determined a twoway interaction between treatment and time for malate dehydrogenase.
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4.4.6 Cytochrome C oxidase activity

Fig.4.6 Activity of cytochrome C oxidase in traumatically brain injured GCEE
treated animals compared to saline treated and sham animals. Bars are
representative of mean ± S.E.M., n = 3 for each group.

The investigation of the catalytic activity of cytochrome C oxidase was
performed using the Cyt-c assay. Activity upon administration of saline and
GCEE in traumatically brain injured rats was determined to be not statistically
significant (p > 0.05), with the greatest increase in activity observed 60 minutes
post injury.
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4.4.7 ATP synthase activity

Fig.4.7 Activity of ATP synthase in traumatically brain injured GCEE treated
animals compared to saline treated and sham animals. Bars are representative of
mean ± S.E.M., n = 3 for each group.

In determining the activity of ATP synthase post-TBI, the ATP synthase
assay was used. Reductions in activity were observed upon the administration of
saline compared to control (Fig.4.7). Despite the increase in activity observed
after the administration of GCEE at both time points compared to saline treated
and sham animals, differences did not achieve statistical significance (p > 0.05).

4.5 Discussion
The pathogenic role of oxidative stress in neurodegenerative disease in
relation to glutathione depletion has been well documented. Research
demonstrates the contribution of oxidative stress to the energy crisis observed
post-TBI. Studies show the attenuation of oxidative stress experienced upon
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traumatic brain injury impedes the disruption of redox homeostasis, which can
improve cellular and functional outcomes after injury. Given the complexity and
heterogeneity of TBI, therapeutic approaches to combat the deleterious effects
are still non-existent. However, the administration of chemical substances, such
as GCEE, in experimental settings have been shown to increase intracellular
glutathione levels, which in turn alleviates neurotoxic byproducts accumulated
upon injury, and offers therapeutic promise. Here we investigated the enzymatic
activity of the energy related proteins glyceraldehyde-3-phosphate
dehydrogenase, pyruvate kinase, lactate dehydrogenase, aspartate
aminotransferase, malate dehydrogenase, cytochrome C oxidase, and ATP
synthase, which were found to be excessively nitrated in moderate TBI, and
assessed the efficacy of GCEE as a potential therapeutic strategy in improving
brain energy metabolism following moderate TBI.
Glyceraldehyde-3-phosphate dehydrogenase is a multifunctional protein
with glycolytic, sensory, and apoptotic activities expressed ubiquitously in
tissues. Studies demonstrate the functional role of glyceraldehyde-3-phosphate
dehydrogenase in the progression of neurodegenerative disease, as impaired
glycolytic function and increased pro-apoptotic function is observed in
Alzheimer’s and Huntington’s disease (AD and HD, respectively) (Butterfield et
al. 2010, Hara et al. 2006, Nicholls, Li, and Liu 2012). In glycolysis, this cytosolic
enzyme catalyzes the oxidative phosphorylation of glyceraldehyde-3-phosphate
to 1, 3-biphosphate glycerate by converting NAD+ to NADH. The catalysis of this
reaction also produces ATP through substrate level phosphorylation. Impairment
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of GAPDH glycolytic activity in persons who have experienced TBI may
contribute to an increased concentration of glyceraldehyde-3-phosphate and
dihydroxyacetone. The accumulation of both compounds give rise to
methylgloxal, a highly oxidative metabolite associated with DNA and protein
modification (Murata-Kamiya and Kamiya 2001). During pathologic conditions of
oxidative stress, such as those experienced in the brain through TBI,
glyceraldehyde-3-phosphate dehydrogenase inactivation triggers cell death
signaling pathways through aggregation, translocation, and binding (SchuppeKoistinen et al 1994, Tarze et al 2007). Specifically, the accumulation and
translocation of cytosolic GAPDH to the nucleus increases levels of DNA
damage and inhibits DNA repair, which may in turn induce transcription of cell
death mediated genes (Butterfield et al 2010). The mitochondrial binding of
GAPDH is associated with apoptosis via membrane depolarization, which
respectively leads to calcium uptake, matrix swelling, and the release of
cytochrome C (Butterfield et al 2010). Attenuation of oxidative stress via
administration of GCEE following traumatic brain injury may improve
maintenance of glycolytic function while simultaneously reducing neuronal cell
death commonly observed in TBI.
In the final step of glycolysis, pyruvate kinase converts
phosphoenolpyruvate (PEP) to pyruvate, which produces ATP through substrate
level phosphorylation. Pyruvate kinase exists in four isoforms: M1, M2, R, and L.
Pyruvate kinase M1 is typically expressed in the brain. Evidence indicates
reduced enzyme activity of PK in individuals with amnestic mild cognitive
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impairment (MCI), a predecessor condition frequently experienced upon
development of Alzheimer’s disease, and posits that protein function is impaired
by oxidative modification (Reed et al 2008). Given its glycolytic nature, pyruvate
kinase is vital to the production of energy in the brain, as pyruvate produced by
its catalytic activity acts as an intermediate to continue cellular respiration.
Oxidative modifications of pyruvate kinase observed in individuals with MCI have
been suggested to result in limited ATP production and altered ATP-dependent
cellular activities, such as signal transduction and cell membrane potential
maintenance (Reed et al 2008). Similar manifestations may be observed in
persons with TBI, as pyruvate kinase is also found to be oxidatively modified.
The significantly increased enzyme activity of PK upon the administration of
GCEE 30 and 60 minutes compared to sham and saline treated animals
following traumatic brain injury suggests potential improvements of redox
homeostasis and ATP production outcomes following TBI.
Lactate dehydrogenase, a cytoplasmic enzyme, exists in five isoforms.
Although the isoforms have similar catalytic functions, their tissue distribution
varies. LDH-1 is expressed within the brain. Damage to tissues results in
increased serum levels of LDH, respective of isozyme expression in tissue type.
Thus, the utilization of serum LDH levels as a biomarker are of clinical interest,
as it reflects pathological conditions of specific tissues. Under glycolytic
conditions, the reduction of pyruvate to lactate is catalyzed by lactate
dehydrogenase using NADH. The utilization of lactate as a substrate for
gluconeogenesis ensures the perpetuation of glucose and energy metabolism, in
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circumstances of limited glucose availability. Lowered glucose metabolism
attributed to LDH dysfunction has been observed in AD, Parkinson’s disease
(PD), and MCI (Reed et al 2008, Hoyer 2004). Impairment in the catalytic activity
of lactate dehydrogenase via oxidative modifications could result in reduced
gluconeogenesis and the overproduction and/or accumulation of pyruvate (Reed
et al 2008). Inhibition of protein oxidative damage associated with TBI via
administration of GCEE may increase LDH enzymatic activity, which may
successively result in increased brain lactate levels, glucose production, NAD+
production, and energy metabolism.
Aspartate aminotransferase is a transaminase that exists as two forms,
cytosolic and mitochondrial. Its expression can be observed in multiple tissues,
including the brain, liver, heart, skeletal muscle, kidneys, and red blood cells.
Similar to LDH, serum levels of AST are used as a biomarker to assess extent of
injury in pathological conditions. Aspartate aminotransferase catalytic function is
vital to amino acid metabolism, as it is responsible for the interconversion of
oxaloacetate and glutamate to aspartate and α-ketoglutarate. α-ketoglutarate
generated from the anaplerotic transamination of glutamate serves as a key
intermediate in the TCA cycle via cyclization continuation and production of
NADH. Impairments in AST activity may contribute to the increased
concentration of glutamate observed following primary TBI. Here we report
increased enzymatic activity following the administration of GCEE 60 minutes
post-TBI compared to saline treated and sham. The ability of GCEE to impede
the cascade of ROS production resulting from glutamate-induced excitotoxicity
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and increased calcium influx may alleviate AST inactivation due to protein
oxidation.
Malate dehydrogenase is an oxidoreductase that exists within the cell as
either a mitochondrial or cytoplasmic isozyme. Mitochondrial MDH participates in
the oxidation of malate to oxaloacetate using NAD+, in the final step of the TCA
cycle before regeneration, while cytoplasmic MDH participates in the malateaspartate shuttle which permits the passage of malate through the mitochondria
membrane for conversion into oxaloacetate via exchange of reducing
equivalents. Malate dehydrogenase has been shown to be oxidatively modified in
persons with MCI (Reed et al 2008), and its activity has been demonstrated to be
elevated in persons dying of AD (Shi and Gibson 2011, Bubber et al 2005, Oop
den Velde and Stam 1976). Impairments in the activity of MDH may result in
reduced oxaloacetate and ATP production in persons with TBI. Increases in MDH
activity may elevate oxaloacetate levels, which may in turn decrease the
increasingly high levels of glutamate (and excitotoxicity) experienced after brain
injury, as oxaloacetate has been demonstrated to scavenge glutamate (Zlotnik et
al 2010). Increases in MDH activity may also increase oxaloacetate levels and
passage of reducing equivalents to ETC, which may profoundly increase the
reduced ATP production exhibited in TBI affected individuals. In this current
study, we have demonstrated that the administration of GCEE significantly
increases MDH activity in TBI rats, where treatment administered 60 minutes
post injury significantly increases activity compared to treatment administered at
30 minutes. The ability of GCEE to increase activity suggest its efficacy as a
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therapy to attenuate oxidative stress and increased MDH susceptibility to
oxidative modification.
Cytochrome C oxidase, also known as Complex IV of the electron
transport chain, catalyzes the transfer of electrons from ferrocytochrome c to
molecular oxygen, and the conversion of molecular oxygen to water. In mammals
this enzyme consists of 13 subunits responsible for regulatory, assembly, and
catalytic functions. Three of the subunits have catalytic function, while the other
10 subunits have regulation and assembly function. The activity of Cyt-C is said
to be an indicator of the oxidative capacity of cells under normal physiological
conditions (Srinivasan and Avadhani 2012). Under normal physiological
conditions, the mitochondria produce ROS in small amounts. As a result of brain
injury, the opening of the mitochondrial permeability transition pore initiates the
overproduction of ROS and apoptosis via cytochrome C release. Observations of
deficient cyt-C activity via protein dysfunction has been correlated with clinical
and experimental manifestations of mitochondrial dysfunction resulting in Leigh
syndrome, stroke, AD, PD, and TBI (Nelson and Silverstein 1994, Hovda et al
1991). Reduced alterations in cytochrome C oxidase activity may directly affect
cellular ATP levels and calcium homeostasis. The attenuation of oxidative stress
via administration of GCEE may indirectly increase ATP levels in individuals
suffering from traumatic brain injury by improving mitochondrial function,
decreasing calcium influx, and decreasing susceptibility of Cyt-C to oxidative
modifications.
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ATP synthase, also known as Complex V of the electron transport chain,
plays a key role in energy production and transduction in cells. ATP synthase is
an enzyme whose catalytic mechanism involves the utilization of energy from the
proton gradient established by the ETC to synthesize ATP via phosphorylation of
ADP. Reduced energy metabolism as well as mitochondrial dysfunction has been
subsequently observed in TBI, as well as other neurodegenerative disease, as a
consequence of oxidative stress and damage. Here we report reduced activity of
ATP synthase upon brain injury compared to the control, which is not statistically
significant. Reductions in ATP synthase activity are indicative of oxidative
modifications incurred by protein via increased ROS/RNS production after TBI,
possibly resulting in depressions in ETC and impaired ATP production. The
administration of GCEE following injury resulted in non-significant increases in
ATP synthase activity. This suggests that the GCEE is protective in reducing the
oxidative modifications of ATP synthase experienced post traumatic brain injury.
In this study, we assessed the enzymatic activity of energy related
proteins identified as being excessively nitrated. Oxidative modification of
proteins contribute to the alterations of enzyme activities found in many
neurodegenerative disorders. Slight reductions in the activities of some energy
related proteins were observed upon the administration of the vehicle following
TBI, where pyruvate kinase and aspartate aminotransferase activity were
reduced upon administration at 30 minutes, while ATP synthase activity was
reduced at 30 and 60 minutes. Elevations in activities of glyceraldehyde-3phosphate dehydrogenase, pyruvate kinase, lactate dehydrogenase, aspartate
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aminotransferase, malate dehydrogenase, and cytochrome C oxidase upon
administration of saline are suggestive of saline providing protection from protein
oxidation incurred post injury. The administration of saline solutions containing
hydrogen, pyruvate, and lactate have been shown to diminish the effects of
secondary brain injury by attenuating increased ROS/RNS production, enhancing
bioenergetics, and improving neurological recovery, respectively (Ichai et al
2009). All proteins in this current investigation have been found to be
upregulated, with significant elevations observed in the activities of pyruvate
kinase and malate dehydrogenase. Given that the administration of GCEE
attenuates the overproduction of oxidative stress observed after TBI, elevations
in the activities of proteins upon administration of drug in vehicle compared to
only vehicle suggests saline’s ability to enhance attenuation of oxidative stress.
Trends in activities indicated that administration of GCEE 60 minutes post-TBI
demonstrated the highest level of activity compared to treatment at 30 minutes,
with significant observations of increased activities in pyruvate kinase, aspartate
aminotransferase, and malate dehydrogenase. Taken together, these results
suggests that GCEE is a promising potential therapeutic that increases enzyme
activity of several key energy related proteins upon administration at one hour
following traumatic brain injury.
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CHAPTER 5
SALVAGE ENZYME ANALYSIS MODIFIED BY PROTEIN NITRATION VIA
MODERATE TRUAMATIC BRAIN INJURY
5.1 Overview
Protein dysfunction via protein modification has been observed in
all common forms of TBI, and is a result of cellular redox homeostatic
perturbations. Oxidative modifications in neurodegenerative diseases have been
demonstrated to decrease the enzymatic activity of an enzyme, in comparison to
the controls, as studies have reported an inverse correlation between oxidative
modifications and enzyme functionality, where functional activity decreases as
oxidative modifications increase (Reed et al. 2008, Aksenov et al. 2000,
Butterfield et al. 2006, Poon et al. 2005, Reed et al. 2009). Our data suggests
that cerebral oxidative stress experienced after traumatic brain injury ultimately
leads to reduced purine recycling, as salvage related enzyme hypoxanthineguanine phosphoribosyltransferase (HGPRT) has been demonstrated to be
oxidatively modified. The administration of GCEE post-TBI upregulates cellular
glutathione levels (Reed et al 2009, Drake et al 2002, Lok et al 2011), which in
turn normalizes redox homeostasis via attenuation of ROS/RNS. In an
exploratory effort to assess the efficacy of GCEE as a potential therapeutic
strategy for TBI for the restoration of salvage related enzyme HGPRT,
traumatically brain injured Wistar rats were administered saline or GCEE, with
the exception of sham animals, 30 minutes post injury. The enzymatic activity of
hypoxanthine-guanine phosphoribosyltransferase was then determined
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spectrophotometrically using brain homogenate. A non-significant increase in the
activity of HGPRT was observed in animals treated with GCEE compared to
saline treated animals (p > 0.05). Results suggest the correlation of elevated
antioxidant capacity with increased enzyme activity. Thus, the elevation of
glutathione via GCEE administration post injury indicates the therapeutic promise
of GCEE as a potential strategy in the restoration of hypoxanthine-guanine
phosphoribosyltransferase following traumatic brain injury.

5.2 Introduction
Purine nucleotides are active participants in a wide variety of biochemical
processes, such as cell signaling. The strict regulation of their biosynthesis and
metabolism are therefore important. Purine nucleotides may be assembled from
“scratch” via de novo synthesis, or “recycled” from preformed bases via salvage
pathway. The brain depends on the latter mechanism in preserving purine pools,
as it has a limited capacity for de novo synthesis.
Our findings are the first to report purine salvage enzyme hypoxanthineguanine phosphoribosyltransferase as being oxidatively modified upon TBI.
Oxidative stress, a hallmark of TBI, is characterized by an imbalance between
prooxidants and antioxidants. Failure to attenuate oxidative stress is the result of
the body’s inability to counteract the enhanced formation of toxic radical species.
Depletion of glutathione levels upon brain trauma increases cellular components
susceptibility to oxidative modifications, such as structural and functional
alterations, which ultimately contributes to cellular dysfunction and death. GCEE,
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a potential therapeutic strategy for TBI, exhibits antioxidant activity by increasing
glutathione production. Elevations in intracellular glutathione levels restore redox
homeostasis, which improves cell functional outcomes post-TBI. In this present
study, we assessed the enzymatic activity of HGPRT after experimental TBI and
the administration of treatment by conducting a spectrophotometric assay.

5.3 Materials and Methods
5.3.1 Chemicals and Materials
All chemicals utilized were obtained from Novocib (Lyon, France) with
the exception of GCEE, purchased from Bachem (Torence, CA, USA), PRPP,
which was purchased from Thermo Fisher Sigma Aldrich (St. Louis, MO, USA).
5.3.2 Surgical, Treatment, and Sample Preparation
Please refer to Chapter 3, sections 3.1.1, for information regarding
surgical procedures. For information regarding to treatment and sample
preparation, please refer to Chapter 4, section 4.3.2.
5.3.3 Hypoxanthine-guanine phosphoribosyltransferase assay
Please refer to Chapter 3, section 3.1.3.8, for more information regarding
the quantification of HGPRT activity using the PRECICE ® HPRT Assay
(http://www.novocib.com/HPRT_Assay_Kit).
5.3.4 Statistical Analysis
Data was analyzed using ANOVA. Statistical significance was set at p <
0.05.
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5.4 Results
The catalytic activity of HGPRT was determined using the hypoxanthineguanine phosphoribosyltransferase assay. A non-significant reduction in activity
was observed upon the treatment of saline 30 minutes post brain injury
compared to sham animals (Fig.5.1). The administration of GCEE nonsignificantly increased activity compared to saline (p = 0.0963); however, it did
not restore activity to levels seen in the control, as a slight non-significant
reduction in activity was observed (p < 0.05).

Fig.5.1 Activity of hypoxanthine-guanine phosphoribosyltransferase in
traumatically brain injured GCEE treated animals compared to saline treated and
sham animals. Bars are representative of mean ± S.E.M., n = 3 for each group.
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5.5 Discussion
Traumatic brain injury is associated with oxidative stress through the
increased production of reactive oxidants. Oxidative modifications contribute to
protein nitration and dysfunction exhibited in all common forms of TBI. The
administration of GCEE following brain trauma elevates glutathione levels and
decreases oxidative damage.
In this study, we investigated whether the administration of GCEE in traumatically
brain injured rats could be utilized as a potential therapeutic strategy in the
restoration of HGPRT via glutathione elevation following the onset of injury.
Hypoxanthine-guanine phosphoribosyltransferase is a cytosolic salvage
enzyme that is expressed in all tissues, and is very abundant in the brain.
Individuals suffering from Lesch-Nyhan syndrome have deficient hypoxanthineguanine phosphoribosyl activity, which results in severe neurological disorders
characterized by the overproduction of uric acid and self-injurious behavior.
Specifically, HGPRT catalyzes the conversion of preformed purine bases,
hypoxanthine and guanine, to inosine monophosphate and guanosine
monophosphate, respectively. Here we report reduced activity of HGPRT upon
traumatic brain injury in animals receiving saline compared to control, which is
not statistically significant. The role of reductions in hypoxanthine-guanine
phosphoribosyltransferase activity may cause a deficit in intracellular GTP and
GTP depletion, despite its indirect participation in the metabolism of guanosine.
Thus, brains of individuals who have brain trauma may experience impaired Gprotein-mediated signal transduction. During signal transduction, a stimulus is
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converted into a cellular response. This conversion is stimulated by the
attachment of a signaling molecule to cell membrane protein receptor, which
elicits changes in cell function via transmission of signal into cell via second
messenger. Glucagon and epinephrine are hormones that distinctly control
glycogen metabolism via response mechanisms. Epinephrine release assists in
the body’s response to a stressor, while glucagon release is to maintain
homeostasis by elevating blood sugar. Glycogen may act as an endogenous
source of metabolic energy, in circumstances when energy metabolism is
reduced, such as TBI. In this work, we demonstrated that the administration of
GCEE 30 minutes following brain trauma non-significantly increased HGPRT
activity to levels almost of normality, referring to activity levels exhibited in control
animals. Our data suggests GCEE may indirectly improve or increase the
metabolism of glycogen upon TBI via attenuation of oxidative damage
experienced by HGPRT upon injury.
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CHAPTER 6
CONCLUSIONS AND FUTURE DIRECTIONS
6.1 Conclusions
Oxidative stress, a hallmark of traumatic brain injury, can cause
perturbations in protein structural and functional activity via oxidative damage.
The body’s innate ability to combat oxidative stress upon TBI is ineffective, as
glutathione is depleted. Research demonstrates the ability of gammaglutamylcysteine to elevate cellular levels of glutathione in the brain (Drake et al
2002). The studies presented in this thesis have investigated the antioxidant
capabilities of GCEE to increase enzymatic activity of proteins identified as
excessively nitrated following TBI.
The utilization of enzyme assays determined the enzymatic activity of
several proteins identified as being excessively nitrated following moderate
traumatic brain injury using GCEE treatment 30 and 60 minutes post injury.
These enzymes include glyceraldehyde-3-phosphate dehydrogenase, pyruvate
kinase, lactate dehydrogenase, aspartate aminotransferase, malate
dehydrogenase, cytochrome C oxidase, ATP synthase, and hypoxanthineguanine phosphoribosyltransferase. The goal of the first study was to test our
hypothesis that GCEE could increase the activity of oxidatively modified energyrelated proteins. Glyceraldehyde-3-phosphate dehydrogenase is responsible for
the conversion of glyceraldehyde-3-phosphate to 1, 3-biphosphate glycerate in
the sixth step of glycolysis (see Fig.3.1) and the production of ATP via substrate
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level phosphorylation. Inactive and impaired GAPDH activity may contribute to
increased oxidative susceptibility of DNA and protein damage via methylgloxal
production and nuclear translocation. The administration of GCEE post injury
increased the enzymatic activity of glyceraldehyde-3-phosphate dehydrogenase
(Fig.4.1, page 43). Administration 60 minutes post injury had a greater effect on
the rats in comparison to those treated with saline 30 minutes following trauma
(Fig.4.1). In the final step of glycolysis, pyruvate kinase assists in the catalysis of
phosphoenolpyruvate (Fig.3.2, page 27), and in the production of ATP through
substrate level phosphorylation. Our findings demonstrate a slight reduction in
PK activity following the administration of saline 30 minutes after TBI compared
to sham; however, activity increased within 60 minutes (Fig.4.2) Reductions in
the activity of PK may result in limited ATP and altered signal transduction and
cell membrane potential maintenance (Reed et al 2008). We also observed a
significant elevation of PK catalytic activity post injury following the administration
of GCEE compared to sham and saline treated animals, where a more
pronounced increase in activity was observed at 60 minutes (Fig.4.2).
Lactate dehydrogenase catalyzes the reduction of pyruvate to lactate
using NADH (Fig.3.3, page 28). Deficient LDH activity could result in reduced
glucose production and the accumulation of pyruvate (Reed et al. 2008). Upon
the administration of the drug, LDH activity increased compared to control and
vehicle animals, where the administration of GCEE 60 minutes post injury had a
greater elevation in activity compared to 30 minutes (Fig.4.3, page 45). Aspartate
aminotransferase converts oxaloacetate and glutamate to aspartate and α65

ketoglutarate (Fig.3.4, page 46). Reduced AST activity may contribute to
increased concentration of glutamate. Our data demonstrates a slight reduction
of activity following the administration of saline 30 minutes after injury compared
to sham, but activity significantly increased within 60 minutes (Fig.4.4, page 62).
We report elevated activity following the administration of GCEE post-TBI
compared to saline treated and sham animals, where activity significantly
increased within 60 minutes (Fig.4.4). Malate dehydrogenase catalyzes the
oxidation of malate to oxaloacetate (Fig.3.5, page 31). Impaired MDH activity
may result in reduced oxaloacetate and ATP production. Administration of GCEE
post-TBI significantly increases MDH activity compared to the control, where
drug administered 60 minutes after trauma significantly increases activity
compared to administration at 30 minutes (Fig.4.5, page 47).
Cytochrome C oxidase catalysis transfers the electrons from
ferrocytochrome c to molecular oxygen, while converting molecular oxygen to
water (Fig.3.6, page 32). Reductions in Cyt-C activity may directly affect ATP
levels and calcium homeostasis. The administration of GCEE upon TBI slightly
increased the enzyme activity of Cyt-C compared to sham animals, where a
greater increase in activity was observed at 60 minutes administration compared
to administration of drug at 30 minutes (Fig.4.6, page 48). ATP synthase
catalyzes the phosphorylation of ADP. Here, we report a reduction in activity of
ATP synthase upon injury compared to control (Fig.4.7, page 34). The
administration of GCEE following trauma increased activity compared to control
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and vehicle groups, where administration of drug 60 minutes had a greater
increase in activity than that of 30 minutes (Fig.4.7).
Hypoxanthine-guanine phosphoribosyltransferase catalysis converts
hypoxanthine to inosine monophosphate and guanine to guanosine
monophosphate (Fig.3.8, page 36). A reduction in HGPRT activity was observed
following TBI (Fig.5.1, page 61). Impaired activity may cause a deficit in GTP and
GTP depletion. Activity increased upon treatment with GCEE compared to sham
and saline treated animals (Fig.5.1).
Reductions in enzyme activity upon traumatic brain injury suggest
enzyme susceptibility to oxidative damage induced by oxidative stress. Protein
oxidative modifications in our study bolsters suggestions of the functional role of
oxidative stress in the progression of neurodegenerative diseases. The loss of
enzyme activity attributed to protein oxidative modifications potentially
contributes to abnormal energy and nucleotide metabolism. The administration of
GCEE demonstrates elevations in enzymatic activity of energy and salvage
related proteins in the brain post-TBI, with more pronounced effects observed
with administration at 60 minutes. This suggests that GCEE may prevent brain
damage against toxic radical species that cause oxidative stress and protein
nitration in traumatic brain injury.
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6.2 Future Studies
1. (Re-analysis) In our experiments, there are three experimental groups:
sham, saline, and GCEE. All groups receive a craniotomy; however, saline
and GCEE groups were further subjected to a moderate TBI via cortical
contusion. To assess the efficacy of GCEE as a potential therapeutic
strategy in restoring enzymatic activity of proteins identified as nitrated
post-TBI, we compared the measurements of activity of enzymes in our
treatment group, GCEE, to the activities of our control and vehicle groups,
sham and saline respectively. In most cases, the administration of saline
30 and 60 minutes post injury exhibited an increase in enzyme activities
compared to sham animals. Given that research indicates that hydrogenrich saline is protective against oxidative damage observed in traumatic
brain injury (Hou et al 2012), the addition of a TBI only experimental group
should be included to confirm whether the enzymatic activities of the
saline group are truly representative of enzyme activities experienced
post-TBI.
2. (Re-analysis) An exploratory effort to investigate the effect of
administration of drug on activity, in a time dependent manner, should be
performed. Our findings indicate the administration of GCEE 60 minutes
post-TBI demonstrate a more pronounced elevation in activity of enzymes
excessively nitrated upon TBI. Here, we only assessed the enzymatic
activity of hypoxanthine-guanine phosphoribosyltransferase upon
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treatment with saline and GCEE 30 minutes following traumatic brain
injury.
3. Although results from both studies in this work are encouraging, indication
of their therapeutic promise should be further examined. Both studies
demonstrated increasing activity of proteins nitrated post-TBI within
experimental animals 30 and/or 60 minutes after injury; however,
realistically speaking, an individual may not have access to treatment 30
or 60 minutes following injury. The delay of treatment upon injury should
be considered, as an individual suffering a mild to moderate TBI may not
exhibit prolonged secondary effects of injury. Thus, they may not feel
inclined to seek treatment. The proposal of potential studies investigating
the effect of GCEE should include administration of treatment at more
realistic time points such as 90 minutes, 120 minutes, and so forth.
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Table 6.1 Supporting data for assessment of glyceraldehyde-3-phosphate
dehydrogenase activity in experimental TBI groups

Groups
(n = 3)
Sham 30
Saline 30
GCEE 30
Sham 60
Saline 60
GCEE 60

Δ Abs
-0.201222
-0.096
-0.152333
-0.241333
-0.189
-0.097
-0.132556
-0.170222
-0.191
-0.2105
-0.12
-0.233333
-0.151167
-0.206
-0.2585
-0.27
-0.217333
-0.234333

Mean

Std.
Deviation

Std. Error
of Mean

% of
control

-0.1499

0.052655

0.0304

100

-0.1758

0.073069

0.042187

117.3

-0.1646

0.029626

0.017105

109.84

-0.1879

0.059939

0.034606

100

-0.2052

0.053671

0.030987

109.19

-0.2406

0.026879

0.015519

127.99

ANOVA
Treatment
Time

P value
0.5063
0.0593
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Table 6.2 Supporting data for assessment of pyruvate kinase activity in
experimental TBI groups

Groups
(n = 3)
Sham 30
Saline 30
GCEE 30
Sham 60
Saline 60
GCEE 60

Δ Abs.
-0.082889
-0.059778
-0.088333
-0.065667
-0.0715
-0.078778
-0.151
-0.066667
-0.143722
-0.041556
-0.067444
-0.053444
-0.053167
-0.0615
-0.068667
-0.1695
-0.069
-0.090167

Mean

Std.
Deviation

Std. Error of
Mean

% of
control

-0.077

0.0152

0.0088

100

-0.072

0.006568803

0.037925

93.482

-0.1205

0.0467

0.027

156.45

-0.0541

0.013

0.0075

100

-0.0611

0.007757314 0.004478688

-0.1096

0.053

ANOVA
Treatment
Time

0.0306

112.86
202.33

P value
0.0129
0.2818

Adjustment for Multiple Comparisons: Tukey
Group
Least Square Mean
Sham
-0.06557407
Saline
-0.06654630
GCEE
-0.11500926

Sham
Saline
GCEE

Least Squares Means for Treatment
Sham
Saline
0.9980
0.9980
0.0226
0.0254
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GCEE
0.0226
0.0254
-

Table 6.3 Supporting data for assessment of lactate dehydrogenase activity in
experimental TBI groups

Groups
(n = 3)
Sham 30
Saline 30
GCEE 30
Sham 60
Saline 60
GCEE 60

Δ Abs.
-0.17844
-0.24711
0.301444
-0.14522
-0.13933
-0.13167
-0.13689
-0.17667
-0.15422
-0.18489
-0.22489
0.353778
-0.12383
-0.12906
-0.15028
-0.18067
-0.18761
-0.17367

Mean

Std.
Deviation

Std. Error of
Mean

% of
control

-0.041

0.2989

0.1725

100

-0.139

0.0068

0.0039

335.36

-0.156

0.0199

0.0115

376.9

-0.019

0.3232

0.1866

100

-0.134

0.014

0.0081

719.94

-0.181

0.007

0.004

967.76

ANOVA
Treatment
Time

P value
0.3513
0.9923
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Table 6.4 Supporting data for assessment of aspartate aminotransferase activity
in experimental TBI groups

Groups
(n = 3)
Sham 30
Saline 30
GCEE 30
Sham 60
Saline 60
GCEE 60

Δ Abs.
-0.44078
-0.27644
-0.38267
-0.45556
-0.34322
-0.29556
-0.411
-0.37567
-0.48989
-0.29711
-0.09689
-0.25222
-0.18567
-0.20033
-0.29144
-0.37156
-0.28067
-0.30767

Mean

Std.
Deviation

Std. Error of
Mean

% of
control

-0.36663

0.083332

0.048112

100

-0.36478

0.082149

0.047429

99.495

-0.42552

0.058479

0.033763

116.06

-0.21541

0.105065

0.06066

100

-0.22581

0.057308

0.033087

104.83

-0.31996

0.046675

0.026948

148.54

ANOVA
Treatment
Time

P value
0.1113
0.0013
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Table 6.5 Supporting data for assessment of malate dehydrogenase activity in
experimental TBI groups

Groups
(n = 3)

Δ Abs.
-0.00996
-0.00788
-0.03112
-0.01325
-0.02958
-0.01383
-0.01498
-0.02508
-0.02838
-0.03092
-0.05017
-0.113
-0.18342
-0.20375
-0.20708
-0.16467
-0.25425
-0.31758

Sham 30
Saline 30
GCEE 30
Sham 60
Saline 60
GCEE 60

Mean

Std.
Deviation

Std. Error of
Mean

% of
control

-0.0163

0.0129

0.0074

100

-0.018889

0.0092663

0.0005499

115.74

-0.022813

0.0069807

0.0040303

139.79

-0.0647

0.0429

0.0248

100

-0.1981

0.0128

0.0074

306.18

-0.2455

0.0768

0.0444

379.48

ANOVA
Treatment
Time
Treatment*Time

P value
0.0025
< 0.0001
0.0041

Adjustment for Multiple Comparisons: Tukey
Group
Least Square Mean
Sham
-0.04050694
Saline
-0.10848611
GCEE
-0.131415625

Sham
Saline
GCEE

Least Squares Means for Treatment
Sham
Saline
0.0200
0.0200
0.004
0.4744
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GCEE
0.0024
0.4744
-

Table 6.6 Supporting data for assessment of cytochrome C oxidase activity in
experimental TBI groups

Groups
(n = 3)
Sham 30
Saline 30
GCEE 30
Sham 60
Saline 60
GCEE 60

Δ Abs.
-0.046
-0.03494
-0.04411
-0.04239
-0.03661
-0.04944
-0.03794
-0.05317
-0.04033
-0.05583
-0.06072
-0.01344
-0.06722
-0.05161
-0.04067
-0.04822
-0.06872
-0.03983

Mean

Std.
Deviation

Std. Error of
Mean

% of
control

-0.041685

0.005913558 0.003414194

100

-0.042814

0.00642726

0.00371078

102.71

-0.043814

0.008186547 0.004726505

105.11

-0.04333

0.026

0.015011

100

-0.05317

0.013346

0.007705

122.69

-0.05226

0.014862

0.00858

120.6

ANOVA
Treatment
Time

P value
0.7178
0.2976
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Table 6.7 Supporting data for assessment of ATP synthase activity in
experimental TBI groups

Groups
(n = 3)
Sham 30
Saline 30
GCEE 30
Sham 60
Saline 60
GCEE 60

Δ Abs.
-0.18433
-0.08456
-0.13622
-0.15367
-0.13244
-0.096
-0.15978
-0.14611
-0.21644
-0.233
-0.1475
-0.02983
-0.08667
-0.0995
-0.17867
-0.17067
-0.1845
-0.21733

Mean

Std.
Deviation

Std. Error of
Mean

% of
control

-0.13504

0.049899

0.028809

100

-0.012737

0.029166

0.016839

94.323

-0.17411

0.037293

0.021531

128.94

-0.13678

0.102007

0.058894

100

-0.12161

0.049826

0.028767

88.911

-0.19083

0.023969

0.01839

139.52

ANOVA
Treatment
Time

P value
0.1528
0.8634
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Table 6.8 Supporting data for assessment of hypoxanthine-guanine
phosphoribosyltransferase activity in experimental TBI groups

Groups
(n = 3)
Sham 30
Saline 30
GCEE 30

Δ Abs.
-0.15983
-0.24
-0.22017
-0.156
-0.11367
-0.09167
-0.16183
-0.1975
-0.2455

Mean

Std.
Deviation

Std. Error of
Mean

% of
control

-0.20667

0.041754

0.024106

100

-0.12044

0.032698

0.018878

58.28

-0.20161

0.041985

0.02424

97.554

ANOVA
Treatment

P value
0.0614
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